Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Accumulated Expenses (2018 - 2024)

Iovance Biotherapeutics (IOVA) has disclosed Other Accumulated Expenses for 4 consecutive years, with $4.0 million as the latest value for Q1 2024.

  • On a quarterly basis, Other Accumulated Expenses fell 7.25% to $4.0 million in Q1 2024 year-over-year; TTM through Mar 2024 was $4.0 million, a 7.25% decrease, with the full-year FY2023 number at $6.6 million, changed N/A from a year prior.
  • Other Accumulated Expenses was $4.0 million for Q1 2024 at Iovance Biotherapeutics, down from $6.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $6.6 million in Q4 2023 to a low of $4.0 million in Q1 2024.